ChemicalBook > Product Catalog >API >Inhibitors >Selumetinib

Selumetinib

Selumetinib is an oral, potent selective mitogen activated protein kinase kinase (MEK) inhibitor, which has been shown to be effective against MEK-dependent tumours. It is intended to treat metastatic uveal melanoma, a rare malignancy that affects the eyes. It is the most common adult intraocular tumour; it arises from melanocytes in the uvea and affects mostly those from White ethnic groups, particularly those with light coloured irises.
Selumetinib Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:AZD 6244
CAS:606143-52-6
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Nanjing Finetech Chemical Co., Ltd.
Tel: 025-85710122 17714198479
Email: sales@fine-chemtech.com
Products Intro: Product Name:Selumetinib
CAS:606143-52-6
Purity:99%min Package:1KG;10KG;100KG;500KG;100g Remarks:ISO certified
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Email: ivan@atkchemical.com
Products Intro: Product Name:Selumetinib
CAS:606143-52-6
Company Name: GIHI CHEMICALS CO.,LIMITED
Tel: 08657186217390
Email: sales@gihichemicals.com
Products Intro: Product Name:Selumetinib
CAS:606143-52-6
Purity:98% HPLC Package:5g/bag;100g/bag;1kg/bag;5kg/bag;25kg/bag
Company Name: Chemwill Asia Co.,Ltd.
Tel: 86-21-51086038
Email: chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com
Products Intro: CAS:606143-52-6
Purity:99% Package:5KG;1KG;25KG PRICE quotation Remarks:Factory stock, quality assurance, price concessions

Lastest Price from Selumetinib manufacturers

  • Selumetinib
  • US $2.00 / kg
  • 2019-04-01
  • CAS:606143-52-6
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
Selumetinib Basic information
Indications and Usage Mechanisms of Action Clinical Research
Product Name:Selumetinib
Synonyms:AZD6244 (Selumetinib,ARRY-142886);ARRY 142886;AZD 6244;5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;Selumetinib AZD624;Esaxerenone;5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-car
CAS:606143-52-6
MF:C17H15BrClFN4O3
MW:457.685
EINECS:
Product Categories:-;MAPK;API;Aromatics;Heterocycles;Inhibitor;Intermediates & Fine Chemicals;Pharmaceuticals;apis;Antineoplastic;Inhibitors
Mol File:606143-52-6.mol
Selumetinib Structure
Selumetinib Chemical Properties
density 1.69
Safety Information
MSDS Information
Selumetinib Usage And Synthesis
Indications and UsageSelumetinib, 1 has a chemical name of 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. It was developed by British company AstraZeneca and is used to treat advanced non-small cell lung cancer (NSCLC). It is mainly used to treat bile duct cancer, colon cancer, NSCLC, etc. Currently, Selumetinib is in stage III clinical trials for treatment of NSCLC.
Mechanisms of ActionSelumetinib is the first mitogenextracellular kinase (MEK1/2) inhibitor to be used in thyroid cancer clinical trials. It inhibits extracellular signal regulating kinase (ERK/2) and activates caspase to dramatically inhibit ERK1/2 phosphorylation.
Clinical ResearchIn phase II clinical trials of radioiodine-refractory papillary thyroid carcinoma, 39 patients took daily oral doses of Selumetinib (100mg bid) for 28 days; results showed that 21 patients’ conditions stabilized (54%), 11 patients’ conditions worsened (28%), 49% patients’ conditions were stable for 16 weeks, 36% patients’ conditions were stable for 24 weeks, and survival terms did not progress to 32 weeks. Negative reactions mainly consisted of rashes (59%), diarrhea (44%), and weakness (41%). Some studies found that after treating 20 patients with thyroid cancer with Selumetinib (75mg bid) for 4 weeks, Selumetinib increased the iodine uptake and retention of patients with radioiodine-refractory papillary thyroid carcinoma. In a blind and random comparative study between a Selumetinib and Docetaxel (DOC) combination treatment group and DOC and placebo treatment group for 87 mutant NSCLSC patients, survival times were 9.4 months and 5.2 months, PFS were 5.3 months and 2.1 months, RR were 37% and 0%, thus showing dramatic differences. Selumetinib’s main negative reactions include neutrophil depletion, dermatitis, and respiratory failure.
UsesIt is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development.
DefinitionChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.
Selumetinib Preparation Products And Raw materials
Tag:Selumetinib(606143-52-6) Related Product Information
Ceritinib (LDK378) Cabozantinib WZ4002 N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide Dacomitinib (PF299804) 1110813-31-4 AP26113 Lenvatinib Afatinib (BIBW 2992) Vandetanib AZD-6244 O-(2-(vinyloxy)ethyl)hydroxylamine Bortezomib MK-2206 2HCl PD 0325901 Trametinib Erlotinib hydrochloride N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide